Articles tagged with Muscle Diseases
A study published in Cell Stem Cell found that mitochondrial dynamics regulate the dormant state of adult muscle stem cells, which are essential for tissue stability. The researchers discovered that the protein OPA1 regulates this process and its depletion leads to severe muscle stem cell defects.
Researchers from Tokyo Medical and Dental University found a novel GLP-1R agonist, PF1801, that can suppress muscle inflammation and restore muscle strength in patients with polymyositis. The study suggests PF1801 could be used to treat patients with muscle wasting disease and improve symptoms associated with inflammatory myopathies.
Researchers at NIH have developed a 3D structure of the twinkle protein, which helps identify mutations that cause mitochondrial diseases. The discovery could lead to targeted treatments for patients with conditions like progressive external ophthalmoplegia and Perrault syndrome.
A new gene therapy approach using the neuroprotective protein SynCav1 has shown promising results in slowing down ALS disease progression and increasing life span in rodent models. The treatment preserved spinal cord motor neurons and extended longevity in mice, with similar effects observed in a rat model of ALS.
A new AI technology called in silico FOCUS analyzes cell images to predict therapeutic effect of drugs for neurodegenerative disorders like Kennedy disease. The technology has 100% accuracy and can analyze several hundred thousand cells in just a few minutes.
Researchers from Tianjin Medical University General Hospital review sarcopenic obesity's impact on liver disease, including nonalcoholic fatty liver disease and cirrhosis. The study aims to clarify the pathogenesis of sarcopenic obesity and identify potential therapeutic avenues.
The authors of a Call to Action emphasize the value of incorporating patient perspectives in clinical Parkinson's disease studies and recommend how to include patient researchers effectively. Patient involvement can help design better studies, ensure tolerable protocols, and improve research outcomes. However, specific challenges must ...
Scientists discover that activating TAK1 in skeletal muscle promotes muscle growth and prevents atrophy, with implications for treating conditions like cancer, COPD, and genetic diseases. The research also highlights the importance of maintaining healthy neuromuscular junctions.
Scientists at Johns Hopkins Medicine have successfully cultivated human muscle stem cells capable of renewing themselves and repairing muscle tissue damage in mice. The self-renewing stem cells were created by reprogramming laboratory-grown human skin cells, which then differentiated into specific cell types using a nutrient-rich broth.
A new cell therapy has shown promising results in slowing the progression of Duchenne muscular dystrophy, a rare genetic disorder. The treatment uses heart cells to improve skeletal muscle and heart function, offering a potential cure for advanced disease cases.
A study at McMaster University found that cycling for 35 minutes three times a week increased overall fitness in people with myotonic dystrophy by 32%. Patients also saw significant gains in muscle mass and reductions in body fat.
A new study found that exercising before developing cancer reduced tumor growth and cachexia symptoms in mice. Regular exercise improved cardiac structure and function, and helped slow tumor growth even after cancer was induced.
A new treatment approach has been proposed for children with congenital muscle disorders, using inhibitors to improve muscle function and movement in mice with mutations in the RYR1 gene. The therapy targets genetic material overload caused by excessive enzyme production, leading to reduced access of genes to cellular machinery.
Professor Antonio Cherubini has made significant contributions to the field of geriatric medicine and musculoskeletal diseases. He is recognized for his work on aging, bone health, and age-related diseases.
The IOF Skeletal Rare Diseases Academy has awarded grants to six young researchers for their outstanding work on rare skeletal disorders. The awards recognize the importance of advancing knowledge and diagnosis for these conditions.
Researchers at the University of Maine used zebrafish to test the effectiveness of neuromuscular electrical stimulation (NMES) on muscle strength and structure. The study found that only one NMES regimen, endurance neuromuscular stimulation (eNMES), improved muscle health when combined with an antioxidant and a specific receptor.
A clinical trial at UC Davis Health showed that cellular therapy offers promise for patients with late-stage Duchenne muscular dystrophy, stopping deterioration of upper limb and heart functions. The therapy appears to be safe and effective in improving skeletal muscle and cardiac function.
A new DNA test has been developed to identify a range of hard-to-diagnose neurological and neuromuscular genetic diseases quicker and more accurately than existing tests. The test uses Nanopore sequencing technology to scan for abnormally long repeats within patients' genes, which are the hallmarks of disease.
The guidelines provide evidence-based recommendations for managing symptoms and improving access to multidisciplinary care for children with CMT. The guidelines promote optimal, standardized care globally and are critical for clinical trial readiness.
Researchers at Tohoku University developed a new lab-based system to grow human muscle cells that contract vigorously. They found that muscle cells from patients with sporadic inclusion body mitosis (sIBM) have similar muscular properties to healthy humans but exhibit altered responses to exercise.
A study suggests that targeting necroptosis in muscle fibers using an inhibitor can lessen myositis-induced muscle weakness and cell death, promoting muscle regeneration. This approach shows promise for treating polymyositis with potentially fewer infectious complications than current immunosuppressive therapies.
A novel biomarker, interleukin-6 (IL-6), has been identified as a potential severity biomarker for facioscapulohumeral muscular dystrophy (FSHD). Elevated IL-6 levels correlate with disease severity in FSHD patients, suggesting its use in assessing disease progression and evaluating treatment efficacy.
Researchers discovered that deficient mitophagy leads to human disease and developed a method to analyze mitochondrial recycling in diseased muscle. Pharmacological activation of mitophagy reversed the progression of mitochondrial muscle disease, offering potential treatment for this condition.
Researchers at EPFL's School of Life Sciences discovered that blocking sphingolipid synthesis can reverse the symptoms of Duchenne muscular dystrophy, including loss of muscle function and inflammation. This study identifies sphingolipid inhibition as a potential treatment for muscular dystrophies.
A study found that a daily supplement of urolithin A improved muscle function and reduced inflammation in older adults. The supplement, produced by gut bacteria, was shown to stimulate mitophagy, a process that recycles damaged mitochondria.
An international team led by the University of Ottawa has published findings on the importance of the enzyme GCN5 in maintaining muscle integrity. The study discovered that GCN5 plays a crucial role in boosting the expression of key structural proteins, notably dystrophin.
Fibrodysplasia ossificans progressiva (FOP) may be rooted in impaired and inefficient muscle tissue regeneration, which enables unwanted bone growth. This discovery could lead to new therapies targeting both extra-skeletal bone formation and muscle function.
This special issue celebrates the career of Professor Terence Partridge, who has enriched our understanding of skeletal muscle cell biology and muscular dystrophy. His research led to the development of therapeutic approaches for neuromuscular diseases like Duchenne muscular dystrophy.
Researchers at Penn State will investigate ways to stimulate muscle growth by increasing ribosome production. Their goal is to find molecular targets that can be used to promote muscle growth without exercise or drugs. This study aims to prevent muscle loss due to aging, cancer, and other chronic diseases.
Researchers developed a non-muscle targeted gene therapy that enhances muscle fiber repair and improves muscle function in LGMD 2B patients. The treatment, administered via a single injection, reduces muscle degeneration and restores myofiber size and muscle strength.
Researchers discover novel compound AD732 with anti-inflammatory and analgesic properties, outperforming standard NSAIDs while causing minimal harm. The compound may be a safer alternative for treating pain and inflammation in difficult diseases like ulcerative colitis and Crohn's disease.
The Adult North Star Network's guidelines aim to improve quality of life for adults with Duchenne muscular dystrophy by addressing complex medical needs such as cardiac failure, weight loss, and renal dysfunction. The consensus-based recommendations also highlight gaps in current care and call for further research.
Researchers found that some individuals with probable sarcopenia can improve after five years, suggesting the condition is modifiable. Factors such as physical activity and cognitive function are associated with improved outcomes.
A new study by USC researchers uses GANs to generate synthetic neurological data that can be fed into machine-learning algorithms to improve BCI usability. This approach improved BCI training speed by up to 20 times and enabled rapid adaptation to new subjects.
Recent clinical and experimental data suggest that vascular calcification and bone loss share common pathophysiological mechanisms. The International Osteoporosis Foundation's new review elucidates the key associations between the two disorders.
A recent study published in the American Journal of Roentgenology found a link between COVID-19 mRNA vaccination and myocarditis in adolescent males. Cardiac MRI was used to assess suspected myocarditis post-vaccination, with late gadolinium enhancement persisting in two patients undergoing repeat MRI.
Researchers at Massachusetts General Hospital have discovered the molecular changes triggered by converting skin cells into immature muscle cells. The findings may lead to generating patient-matched muscle cells for treating muscle injuries and conditions like muscular dystrophy.
Researchers found that inflammatory markers were high when patients experienced episodes of rhabdomyolysis, and lower when they were well. The team identified a 'cytokine storm' as the underlying issue, which can be triggered by an unknown mechanism in VLCADD patients.
Becker disease is caused by unusual electrical activity in muscle fibers, leading to temporary inactivity and weakness. Researchers identify the mechanisms behind this phenomenon and propose potential new therapies.
Researchers aim to characterize sIBM disease progression and explore biomarkers associated with the disease to design more effective clinical trials. The study will enroll 150 subjects and investigate differences in disease phenotype and disease progression, including muscle pathology.
A team of scientists has discovered that muscle fibers contain a surprising variety of nuclei with distinct gene expression patterns. This finding could help better understand muscle diseases such as Duchenne muscular dystrophy and shed light on the underlying mechanisms of cellular function.
The University of Cincinnati researcher is studying the role of a muscle protein in the development of distal arthrogryposis, a rare skeletal muscle disorder. The protein in question, myosin binding protein-C, has been found to be essential for muscle formation, function, and regulation in both heart and skeletal muscles.
Researchers have identified metformin as a potential treatment for myofibrillar myopathies, a group of rare genetic disorders causing progressive muscle wasting. The study's findings, published in Autophagy, show that metformin can prevent muscle disintegration and restore swimming ability in zebrafish models.
Two important breakthroughs will be presented by Institute of Myology experts: a new genetic diagnosis for myopathy triggered by specific mutations, and an MRI study identifying spinal cord degeneration in ALS and FTD patients. The Muscle Atlas database will accelerate research, diagnosis, and therapeutic approaches.
Unverricht-Lundborg disease is more prevalent in Finland due to a genetic mutation that affects the Finnish population. Patients with EPM1 have a higher risk of premature death than the general population, but individual outcomes vary widely.
A team of scientists identified a gene mutation that causes distal arthrogryposis (DA), a condition characterized by joint deformities and muscle loss. The MYLPF gene plays a crucial role in normal muscle development and function, and its mutations can lead to reduced muscle strength and degeneration.
Researchers report that vitamin B3 niacin boosts energy metabolism and slows disease progression in mitochondrial myopathy patients by increasing NAD+ levels in blood and muscle tissue. The study reveals niacin's therapeutic effect in delaying disease progression, offering a promising treatment option for this progressive muscle disease.
A new experimental model of severe Duchenne muscular dystrophy (DMD) reveals that high TGFβ activity suppresses muscle regeneration and promotes fibroadipogenic progenitors, leading to muscle degeneration. The study identifies correcting the muscle micro-environment caused by high TGFβ as a therapeutic target.
Researchers used in vivo imaging to observe how cells move and generate forces in living tissues, revealing new clues on why MYH9 gene mutations lead to various diseases. The study demonstrates that altered myosin activity results in defects in epithelial morphogenesis due to slower cell movements.
A novel study found that fatigue symptoms in Parkinson's Disease are associated with low diastolic blood pressure throughout the day. This association may lead to the development of new treatments targeting DBP without exacerbating cardiovascular effects.
Researchers have successfully developed and tested a gene therapy approach using CRISPR-Cas9 technology to treat Steinert's myotonic dystrophy, a devastating neuromuscular disease. The study showed that the expanded CTG triplet repeat in the DMPK gene was 'cut' and removed from the gene, reducing toxic RNA aggregates in muscle cells.
A $2.88 million NIH grant supports Jingsong Zhou's work to preserve mitochondria and understand the mechanisms behind ALS deterioration. Her novel approach investigates the theory that ALS affects the physiology of the whole body through defective cells in multiple organs.
Researchers at WashU Medicine have discovered a previously unknown autoimmune muscle disease causing sudden onset of debilitating muscle pain and weakness. The syndrome can be effectively treated with anti-inflammatory drugs, but accurate diagnosis is crucial to manage related symptoms.
Cardiomyopathies in children are a life-threatening condition with symptoms including difficulty breathing, heart rhythm abnormalities, and swelling. Research highlights the need for better understanding of the causes to provide effective treatments and improve outcomes for affected children.
Researchers have described a new muscular disease called Myoglobinopathy, caused by a mutation in the myoglobin gene. The study, led by IDIBELL, identifies characteristics lesions in muscle biopsies and altered biochemical properties of mutated myoglobin.
A study from the Intermountain Healthcare Heart Institute has identified eight new gene mutations that may cause or contribute to idiopathic dilated cardiomyopathy, a form of heart disease not caused by known external influences. The researchers found that at least 40% of patients have an underlying genetic cause for the disease.
Scientists at the University of Texas Health Science Center have engineered a novel human stem cell line for skeletal muscle, enabling faster and more efficient generation of muscle stem cells. The breakthrough could lead to disease modeling, gene correction, and potential cell therapy for patients with muscle disorders.
A new natural history study of Amish nemaline myopathy provides a platform for exploring gene replacement therapy. The study's findings show promise for treating the lethal disorder, which is linked to a mutation of the TNNT1 gene.
Researchers found that supplementing mitofusion 2 protein could prevent nerve degeneration, muscle atrophy, and paralysis in a mouse model of Lou Gehrig's disease. The study suggests this approach may be a novel therapeutic strategy for the disease.
Researchers identify myofibroblasts as key players in activating nucleus movement, potentially leading to new therapeutic strategies for muscle disorders. The discovery could improve understanding of muscle differentiation, functionality, and regeneration.